These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

950 related items for PubMed ID: 23764078

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schröder FH, Jones TH, Porst H, Hackett G, Wheaton OA, Martin-Morales A, Meuleman E, Cunningham GR, Divan HA, Rosen RC, RHYME Investigators.
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study.
    Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Brown BT, McVary KT, Te AE, Gholami SS, Rashid P, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rukstalis DB.
    J Urol; 2013 Dec; 190(6):2161-7. PubMed ID: 23764081
    [Abstract] [Full Text] [Related]

  • 8. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
    Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A.
    Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK, Oefelein MG.
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [Abstract] [Full Text] [Related]

  • 12. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
    Bhasin S, Travison TG, Pencina KM, O'Leary M, Cunningham GR, Lincoff AM, Nissen SE, Lucia MS, Preston MA, Khera M, Khan N, Snabes MC, Li X, Tangen CM, Buhr KA, Thompson IM.
    JAMA Netw Open; 2023 Dec 01; 6(12):e2348692. PubMed ID: 38150256
    [Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP, Gardette J, Rollet J, Legros JJ.
    BJU Int; 2013 May 01; 111(6):880-90. PubMed ID: 23294726
    [Abstract] [Full Text] [Related]

  • 14. Progression and treatment of incident lower urinary tract symptoms (LUTS) among men in the California Men's Health Study.
    Wallner LP, Slezak JM, Loo RK, Quinn VP, Van Den Eeden SK, Jacobsen SJ.
    BJU Int; 2015 Jan 01; 115(1):127-33. PubMed ID: 24840926
    [Abstract] [Full Text] [Related]

  • 15. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL, Morgentaler A.
    J Urol; 2003 Dec 01; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [Abstract] [Full Text] [Related]

  • 16. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G.
    Aging Male; 2016 Dec 01; 19(1):64-9. PubMed ID: 26742589
    [Abstract] [Full Text] [Related]

  • 17. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G.
    Postgrad Med; 2013 Mar 01; 125(2):30-9. PubMed ID: 23816769
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD.
    J Androl; 2002 Mar 01; 23(6):922-6. PubMed ID: 12399540
    [Abstract] [Full Text] [Related]

  • 19. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M.
    Int J Impot Res; 2013 Jan 01; 25(1):24-8. PubMed ID: 22971614
    [Abstract] [Full Text] [Related]

  • 20. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
    Okada K, Miyake H, Ishida T, Sumii K, Enatsu N, Chiba K, Matsushita K, Fujisawa M.
    Am J Mens Health; 2018 Sep 01; 12(5):1403-1408. PubMed ID: 27256990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.